EVO
Evotec SEPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Jul 13 Evotec SE reported preliminary Q2 2026 results with EPS of -€0.69, a…
- X Jul 31 Short interest jumps 68.6% to 47.6K
- R Aug 13 Evotec SE reported H1 2026 results showing a sharp decline in financ…
- X Aug 31 Short interest jumps 80.2% to 91.4K
- X Sep 30 Short interest falls 78.5% to 22.1K
- R Oct 14 Mubadala Investment Company PJSC and its affiliates have completely…
- R Oct 15 Evotec SE announced the appointment of Dr. Joanna Holbrook as Chief…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 3 trimmed or exited.
- AnalystsMIXED
4 of 12 rate it Buy or better.
- EstimatesFALLING
Current-quarter EPS estimate −$0.205 → −$0.315 over 90 days. 0 up, 2 down in 30 days.
- TrendDOWNTREND
11% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 6.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| LPL Financial LLC | ADD | $464.9K |
| MILLENNIUM MANAGEMENT LLC | NEAR_EXIT | $63.9K |
| Vanguard Personalized Indexing Management, LLC | TRIM | $38.1K |
| Farther Finance Advisors, LLC | ADD | $48.00 |
| Mubadala Investment Co PJSC | EXIT | $0.00 |
| Optiver Holding B.V. | DOUBLED | $708.9K |
| LPL Financial LLC | ADD | $305.9K |
| ENVESTNET ASSET MANAGEMENT INC | ADD | $298.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 14, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jul 15, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.32 | -$0.38–-$0.25 | -26.0% | $138.7M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $0.07 | $0.07–$0.07 | +120.6% | $721.4M |
Short side
FINRA· Oct 15, 2026SecBot reports
9 filings · 1 bullish · 5 bearish · 3 neutral- BEARISH 6-KOct 15, 2026
Evotec SE announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and…
The complete exit by a major sovereign wealth fund (Mubadala) from a prior 5.62% stake is a significant bearish signal, especially given the activist context from the SC 13D/A filed one day prior…
- BEARISH SC 13D/AOct 14, 2026
Mubadala Investment Company PJSC and its affiliates have completely divested their entire stake in…
The complete exit of Mubadala removes a key activist catalyst that was pushing for a Just-Evotec Biologics carve-out IPO and board refresh. Without this pressure, the likelihood of near-term…
- BEARISH 6-KOct 14, 2026
Evotec SE released preliminary unaudited nine-months 2026 results showing Group revenues of…
The preliminary figures show revenue tracking below the pace needed to reach full-year guidance without a very strong Q4, while the adjusted EBITDA loss through nine months already exceeds the…
- NEUTRAL 6-KSep 29, 2026
Evotec announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective…
Monitor the appointment of a new CSO for any strategic pivot in R&D direction, but this filing alone is a routine succession event with no immediate stock catalyst.
All EVO filing & press-release reports (9)
- 6-K reportOct 15, 2026
- SC 13D/A reportOct 14, 2026
- 6-K reportOct 14, 2026
- 6-K reportSep 29, 2026
- 6-K reportSep 9, 2026
- 6-K reportAug 13, 2026
- PRESS-RELEASE reportJul 13, 2026
- 6-K reportJun 30, 2026
- 6-K reportJun 17, 2026